{
    "Case ID": "056139",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and enforceability"
    ],
    "Legal_Issue": [
        "Validity of the '393 patent against generic version of amlodipine besylate"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations",
        "Patent Act"
    ],
    "Procedural_Stage": [
        "Judicial review under NOC Regulations"
    ],
    "Evidence_Assessment": [
        "Expert evidence on utility, sufficiency, and obviousness"
    ],
    "Decision_Outcome": [
        "Application allowed; Pharmascience's invalidity challenge rejected"
    ],
    "Burden_of_Proof": [
        "On Pharmascience to prove invalidity"
    ],
    "Credibility_Factor": [
        "Expert testimonies evaluated by the court"
    ],
    "Legal_Rule": [
        "Patent must meet requirements for sufficiency, utility, and non-obviousness"
    ],
    "Standard_of_Review": [
        "Standard applicable in judicial review under NOC Regulations"
    ],
    "Procedural_Issue": [
        "Preclusion from relitigating obviousness due to prior litigation"
    ],
    "Grounds_for_Claim": [
        "Invalidity based on insufficiency, lack of utility, and obviousness"
    ],
    "Outcome_on_Merits": [
        "Pfizer succeeded on merits; patent upheld as valid and enforceable"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "In favor of Pfizer"
    ],
    "Review_Standard": [
        "Reasonableness or correctness, depending on issue"
    ],
    "Procedural_Fairness_Assessment": [
        "Proceedings conducted with procedural fairness under NOC framework"
    ],
    "Key_Evidence_Considered": [
        "Patent disclosure",
        "Expert testimony on pharmaceutical efficacy and disclosure adequacy"
    ],
    "Legal_Framework": [
        "Regulatory and statutory framework for drug patents and market approval"
    ],
    "Applicant_Challenge": [
        "Pharmascience challenged validity of Pfizerâ€™s patent"
    ],
    "Court_Result": [
        "Pfizer entitled to prohibition of Notice of Compliance until patent expiry"
    ],
    "Legal_Rule_Source": [
        "Patent Act",
        "NOC Regulations"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Challenged patent on grounds of insufficiency, utility, and obviousness"
    ],
    "Evidence_Type": [
        "Documentary evidence",
        "Expert opinion"
    ],
    "Remedy_Requested": [
        "Order prohibiting Minister from issuing Notice of Compliance"
    ],
    "Outcome": [
        "Remedy granted; marketing barred until patent expires or invalidated"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Interim injunction preventing regulatory approval"
    ],
    "Resolution_Mechanism": [
        "Judicial determination via NOC proceeding"
    ],
    "Legal_Provision": [
        "Section 6 of the NOC Regulations",
        "Patent Act provisions on validity"
    ],
    "Authority": [
        "Minister of Health (regulatory authority subject to court order)"
    ],
    "Claimant_Status": [
        "Pfizer as patent holder and innovator"
    ],
    "Legal_Provision_Cited": [
        "Patented Medicines (Notice of Compliance) Regulations",
        "Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Obviousness challenge precluded by res judicata"
    ],
    "Applicable_Process": [
        "NOC linkage proceedings"
    ],
    "Outcome_of_Review": [
        "Successful for Pfizer"
    ],
    "Pending_Relief_or_Application": [
        "Prohibition of marketing approval pending patent expiry"
    ],
    "Jurisdiction": [
        "Federal jurisdiction, Canada"
    ],
    "Governing_Rule": [
        "NOC Regulations and Patent Act"
    ]
}